Nilsine Partners LLC Acquires 21,730 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Nilsine Partners LLC lifted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 64.8% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 55,249 shares of the biopharmaceutical company's stock after acquiring an additional 21,730 shares during the period. Nilsine Partners LLC's holdings in Catalyst Pharmaceuticals were worth $1,340,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Steward Partners Investment Advisory LLC acquired a new stake in Catalyst Pharmaceuticals during the 4th quarter worth approximately $27,000. Park Square Financial Group LLC acquired a new stake in shares of Catalyst Pharmaceuticals during the fourth quarter worth $29,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock worth $56,000 after acquiring an additional 1,495 shares during the period. Sound Income Strategies LLC bought a new stake in Catalyst Pharmaceuticals in the 1st quarter valued at $64,000. Finally, GAMMA Investing LLC lifted its position in Catalyst Pharmaceuticals by 26.2% in the 1st quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares in the last quarter. 79.22% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Stephens reissued an "overweight" rating and issued a $33.00 price target on shares of Catalyst Pharmaceuticals in a research note on Thursday, February 27th. HC Wainwright restated a "buy" rating and set a $35.00 target price on shares of Catalyst Pharmaceuticals in a report on Friday, February 28th. Cantor Fitzgerald raised Catalyst Pharmaceuticals to a "strong-buy" rating in a report on Thursday, June 5th. Robert W. Baird increased their price objective on Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. Finally, Wall Street Zen raised Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Friday, February 28th. Six analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. According to data from MarketBeat.com, Catalyst Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of $32.83.

Catalyst Pharmaceuticals Price Performance

NASDAQ CPRX traded down $0.53 during mid-day trading on Wednesday, reaching $21.54. 1,194,083 shares of the stock were exchanged, compared to its average volume of 1,106,239. The stock has a market cap of $2.63 billion, a P/E ratio of 13.72, a P/E/G ratio of 0.90 and a beta of 0.72. Catalyst Pharmaceuticals, Inc. has a one year low of $14.75 and a one year high of $26.58. The stock has a 50 day simple moving average of $23.89 and a 200-day simple moving average of $22.89.

Insiders Place Their Bets

In other news, insider Preethi Sundaram sold 1,600 shares of the stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total transaction of $42,272.00. Following the transaction, the insider now owns 41,081 shares of the company's stock, valued at $1,085,360.02. This represents a 3.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Gary Ingenito sold 44,000 shares of the company's stock in a transaction that occurred on Wednesday, May 14th. The stock was sold at an average price of $23.63, for a total value of $1,039,720.00. Following the transaction, the insider now directly owns 68,873 shares in the company, valued at approximately $1,627,468.99. This trade represents a 38.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 247,924 shares of company stock worth $5,879,369. Company insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.